BioTime soars on cell aging reversal

Shares of BioTime shot up over 33 percent this morning after investors got a whiff of a newly published scientific paper in which the biotech company says it was able to reverse the aging process in cells. And scientists for the company say the work has big implications for the development of a new generation of cell-based therapies that can target age-related degenerative diseases. Report

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.